ARTICLE BY BIO X CELL

In vivo functional antibodies

Bio X Cell introduces a comprehensive portfolio of in vivo functional antibodies, designed for sensitive in vivo studies and advanced in vitro applications. Trusted by scientists worldwide and cited in nearly 30,000 peer-reviewed publications, these antibodies are specifically formulated to support reproducible research across a broad range of study areas.

What Are the Specifications of Bio X Cell Antibodies?

Every functional antibody is manufactured to high standards of quality. Researchers utilizing these tools in preclinical models benefit from strict formulations:

• Ultrapure Formulation: All Bio X Cell antibodies feature an ultrapure formulation of ≥95% purity.

• Low Endotoxin: They offer low endotoxin levels, measuring as low as ≤0.5 EU/mg.

• No Additives: Antibodies are free from preservatives, stabilizers, and carrier proteins.

• Lot-Specific CoAs: Each product is accompanied by lot-specific Certificates of Analysis (CoAs), readily available for lab managers and vivarium teams to ensure transparency and compliance.

What Antibody Lines Are Available for Preclinical Research?

With a growing portfolio of over 600 functional antibodies, Bio X Cell offers blocking, neutralizing, activating, and depleting antibodies targeting specific pathways through multiple specialized product lines:

• InVivoMAb: Dependable functional antibodies for in vivo and in vitro applications.

• InVivoPlus: Ultrapure functional antibodies for applications performed under rigorous standards, including binding validation and murine pathogen screening.

• InVivoSIM: Premium research-grade biosimilar antibodies that allow researchers to model a drug’s biological effects without relying on costly pharmaceutical-grade therapeutics.

• RecombiMAb: Recombinant monoclonal antibodies optimized for lot-to-lot consistency to effectively reduce immunogenicity in mouse models.

• Bispecific Antibodies: Premium tools that allow researchers to investigate dual-target mechanisms and engage multiple pathways simultaneously in disease models.